Adjuvant radiotherapy and/or chemotherapy after surgery improves five-year life expectancy for patients with primary pulmonary and mediastinal synovial sarcoma.
Multimodality treatment including surgery followed by adjuvant radiotherapy and/or chemotherapy improves five-year life expectancy in patients with rare primary pulmonary and mediastinal synovial sarcoma.
Sarcoma is defined as a tumor located in the thoracic cavity. However, sarcoma can occur on every side of the body. Synovial sarcoma is a rare soft tissue tumor originating from pluripotent with a high malignancy rate. The most common predilection of synovial sarcoma is in the joints. Primary synovial sarcoma of the lung and mediastinum are rare tumors and generally malignant. There are only a few cases have been reported. Definite diagnosis is made by histopathological, immunohistochemistry, and cytogenetic examination. The management strategy for synovial sarcoma requires multimodality treatment with surgery, chemotherapy, and radiotherapy. However, effective and relatively non-toxic therapy for primary synovial sarcoma is still developed. The five years life expectancy is higher if the patient received adjuvant radiotherapy and/or chemotherapy after surgery.
Dewi et al. (Sat,) conducted a review in Pulmonary and mediastinal synovial sarcoma. Surgery, chemotherapy, and radiotherapy was evaluated. Adjuvant radiotherapy and/or chemotherapy after surgery improves five-year life expectancy for patients with primary pulmonary and mediastinal synovial sarcoma.